Edit
Defence Therapeutics Inc.
https://defencetherapeutics.com/Last activity: 17.02.2025
Probably Closed
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
Visit Website
Visit Website
Investors 1
| Date | Name | Website |
| 17.02.2025 | PowerOne C... | poweroneca... |
Mentions in press and media 16
| Date | Title | Description |
| 06.02.2023 | RETRANSMISSION: Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors | Vancouver, British Columbia--(Newsfile Corp. - February 6, 2023) - Defence Therapeutics Inc. DTC DTC DTCFF ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncol... |
| 03.02.2023 | Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors | Vancouver, British Columbia--(Newsfile Corp. - February 3, 2023) - Defence Therapeutics Inc. DTC DTC DTCFF ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncol... |
| 24.01.2023 | Defence's Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated | Vancouver, British Columbia--(Newsfile Corp. - January 24, 2023) - Defence Therapeutics Inc. DTC DTC DTCFF ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncol... |
| 23.01.2023 | RETRANSMISSION: Defence to Present at the 9th Annual Immuno-Oncology 360º Summit in New-York February 7-10, 2023 | Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Defence Therapeutics Inc. DTC DTC DTCFF ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncol... |
| 20.12.2022 | Breakthrough Results: Defence's Novel AccuTOX(TM) Intranasal Reduced 50% of Cancer Nodules on Animals with Lung Tumors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2022) - Defence Therapeutics Inc. DTC DTC DTCFF ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-onco... |
| 23.11.2022 | Defence's Successfull Study on the AccuVAC-PT007 Vaccine Targeting Cervical Cancer | Vancouver, British Columbia--(Newsfile Corp. - November 23, 2022) - Defence Therapeutics Inc. DTC DTC DTCFF ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-onco... |
| 26.01.2022 | Defence Therapeutics Inc.: Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9 | DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous Defence Therapeutics Inc.: Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9 26.01.2022 / 08:30 The... |
| 30.11.2021 | DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT | DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT 30.11.2021 / 08:30 The issuer is solely responsible for the content of this announcement. CSE: DTC FSE: DTC USOTC: DTCFF... |
| 23.11.2021 | DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER | DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER 23.11.2021 / 08:30 The issuer is solely responsible for the content of this ... |
| 19.10.2021 | Defence Therapeutics Scores Again With New Planned Phase 1 Trial Evaluating Its DC Cancer AccuVAC-D002 Against Melanoma | Defence Therapeutics (OTC Pink: DTCFF) has reached a second milestone in as many weeks after announcing they are close to finalizing the required processes ahead of a pre-IND meeting to initiate a Phase I trial evaluating its DC cancer vacc... |
Show more